



an Open Access Journal by MDPI

T-cell Immunity and Viral Pathogenicity on Vaccine Efficacy

Guest Editors:

Prof. Dr. Clyde S. Crumpacker

Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA

Prof. Dr. Philip W. Askenase

Allergy & Clinical Immunology, Yale School of Medicine, New Haven, CT 06510, USA

Deadline for manuscript submissions:

closed (31 May 2025)

Message from the Guest Editors

Dear Colleagues,

We welcome research articles, reviews, and perspectives that examine, study and contribute conceptually in the development of COVID and effective AIDS vaccines. In the effort to be spearheaded by the editorial office, we will transform the contributions into deep knowledge of vaccinology, and apply Applied Science to further the vaccine development. Contributions in the following are welcome:

1. Studies on the relationship of cytokine storm with the spike protein and/or SARS-CoV-2 replication in lung, kidney or other target organs/tissues
2. Studies of T-cell, B-cell immune response against the spike proteins of SARS-CoV-2 before and/or after COVID vaccine immunization
3. Studies of Kick-Kill (Shock-Kill) and Block-Lock on HIV cure, and/or the strategies on vaccines for HIV cure
4. Model, technology on study of HIV-1 or SARS-CoV-2 pathogenicity

The submission date is 9/6/2022 and deadline is 4/6/2023. Once you are registered, click here to go to the submission form:

<https://susy.mdpi.com/user/manuscripts/upload/00dec7c11d6f14journal=vaccines>

We look forward to hearing from you!



mdpi.com/si/134387

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)